GSK plc (NYSE:GSK) Shares Bought by Bard Financial Services Inc.

Bard Financial Services Inc. raised its position in GSK plc (NYSE:GSK) by 54.6% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 122,245 shares of the pharmaceutical company’s stock after buying an additional 43,150 shares during the period. Bard Financial Services Inc.’s holdings in GSK were worth $4,736,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in GSK. CX Institutional acquired a new stake in shares of GSK in the first quarter valued at about $46,000. Integrated Advisors Network LLC raised its stake in GSK by 6.9% during the first quarter. Integrated Advisors Network LLC now owns 9,714 shares of the pharmaceutical company’s stock worth $376,000 after purchasing an additional 625 shares during the period. SG Americas Securities LLC raised its stake in GSK by 71.4% during the first quarter. SG Americas Securities LLC now owns 18,840 shares of the pharmaceutical company’s stock worth $730,000 after purchasing an additional 7,849 shares during the period. MADDEN SECURITIES Corp raised its stake in shares of GSK by 22.2% in the 1st quarter. MADDEN SECURITIES Corp now owns 106,830 shares of the pharmaceutical company’s stock valued at $4,139,000 after acquiring an additional 19,400 shares during the period. Finally, GAMMA Investing LLC raised its stake in shares of GSK by 107.8% in the 1st quarter. GAMMA Investing LLC now owns 4,447 shares of the pharmaceutical company’s stock valued at $172,000 after acquiring an additional 2,307 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Price Performance

Shares of NYSE GSK opened at $41.30 on Wednesday. The stock has a market cap of $84.65 billion, a price-to-earnings ratio of 25.97, a PEG ratio of 1.12 and a beta of 0.52. GSK plc has a 52 week low of $31.72 and a 52 week high of $44.67. The company’s 50-day moving average price is $37.70 and its 200 day moving average price is $36.51. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.05. GSK had a net margin of 8.13% and a return on equity of 48.59%. The company had revenue of $10.06 billion for the quarter, compared to analysts’ expectations of $7.52 billion. During the same period last year, the company earned $0.43 EPS. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. As a group, research analysts forecast that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be given a $0.4216 dividend. The ex-dividend date of this dividend is Friday, May 16th. This is a boost from GSK’s previous quarterly dividend of $0.39. This represents a $1.69 annualized dividend and a dividend yield of 4.08%. GSK’s dividend payout ratio (DPR) is currently 86.60%.

Analyst Ratings Changes

A number of research analysts recently weighed in on GSK shares. Berenberg Bank restated a “hold” rating on shares of GSK in a report on Tuesday, June 3rd. BNP Paribas started coverage on shares of GSK in a research report on Tuesday, April 15th. They set a “neutral” rating and a $35.25 price objective for the company. Wall Street Zen downgraded shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, May 30th. Morgan Stanley started coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Finally, Hsbc Global Res upgraded shares of GSK to a “strong sell” rating in a research report on Monday, April 28th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, GSK presently has an average rating of “Hold” and an average target price of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.